

GOVERNMENT OF INDIA

Directorate General of Health Services
Central Drugs Standard Control Organization
(Global Clinical Trial Division)

FDA Bhawan, Kotla Road, New Delhi-110002

Te No: 01123236965, Fax: 01123236971

E-mail: dci@nic.in

13381/25/4/2017

File No: CT/18/16-DCG (I)

Date: 07/01/2017

To,

M/s. Boehringer Ingelheim India Private Limited,
1102, 11th Floor, Hall Mark Business Plaza,
Guru nanak Hospital Road, Near Guru Nanak Hospital,
Bandra (East), Mumbai-400051, India.

Subject: Permission for conducting a Phase IIIb clinical trial titled "A 24-week, double-blind randomized, parallel group study evaluating the efficacy and safety of oral nintedanib compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment" – regarding.

Reference: Your letter No.BI/DCGI/CT/046/2016 dated 20/4/2016, on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the investigators mentioned below and as per the Protocol No: 1199.36 local amendment 1.0 dated 06/10/2016 submitted to this Directorate.

1. Dr. Parthiv Mehta, Sanjivani Super Speciality Hospital Pvt. Ltd., 01 Uday Park Society, Near Sunrise Park, Vastrapur, Ahmedabad-380015.
2. Dr. Srikanth Krishnamurthy, Sri Bala Medical Centre and Hospital 901, Trichy Road, Ramanathapuram, Coimbatore-641045, TamilNadu.
3. Dr. Mahavir Modi, Grant Medical Foundation Ruby Hall Clinic, 40 Sassoon Road, Pune-411001, Maharashtra.
4. Dr. Mahendra Mangilal Kawedia, Jehangir Clinical development Centre Pvt. Ltd., Jehangir Hospital Premises, 32 Sassoon Road, Pune-411001, Maharashtra
5. Dr. K. S. Satish, Vikram Hospital Bengaluru Pvt. Ltd., #71/1 Millers Road Opposite to St. Annes's College Bengaluru-560052.
6. Dr. Vellamula Venkat Ram Narsimha Reddy, Kamineni Hospitals Pvt. Ltd., L.B. Nagar, Hyderabad, Telangana-500068
7. Dr. Sanjay Tripathi, Sheth L.G. General Hospital and AMC MET Medical College, Maninagar, Ahmedabad-380008.
8. Dr. B.L. Shashibhushan, Victoria Hospital, BMCRI, Room No. 72/A, 2nd Floor, C Block, Victoria Hospital, BMCRI, Fort, K.R Road, Bangalore-560002.
9. Dr. Raja Dhar, Fortis Hospital, 730 Anandapur, Kolkata-700107, West Bengal.


10. Dr. Anant Mohan, All India Institute of Medical Sciences, Dept. of Pulmonary Medicine and Sleep Disorders, AIIMS, New Delhi, Ansari Nagar, New delhi-110029.
11. Dr. Sushant Meshram, B.J. Government Medical College and Sassoon General Hospitals, Sassoon Road, Somwarpeth, Pune-411001, Maharashtra
12. Dr. George D'Souza, St. John's Medical College and Hospital, Dept. of Pulmonary Medicine, 3rd Floor, PFT lab, New Oncology Building, St. John's Medical College and Hospital, Sarjapur Road, Bangalore-560034.

Kindly note that the clinical trial permission is subject to the following conditions:

- a. PFT test must be conducted at base-line and subsequently at the end of the study.
- b. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- c. Approval of the Ethics Committee shall be obtained before initiation of the study.
- d. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- e. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- f. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within 14 days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- g. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- h. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.
- i. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.
- j. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

- k. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.
- l. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.
- m. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

Yours faithfully,



(Dr. G. N. Singh)

Drugs Controller General (I)

